# Phase 1 Lymphoma, Mantle-Cell trials recruiting: 34 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 34 trials in phase 1 for Lymphoma, Mantle-Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Lymphoma, Mantle-Cell trials: 34 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/lymphoma-mantle-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 34
- Recruiting or not yet: 34
- Read on: November 19, 2026

## Trials

The 25 newest of 34, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 20, 2026 | NCT07883941 | Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid... | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883941) |
| July 13, 2026 | NCT07697339 | HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Mantle Cell Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697339) |
| July 9, 2026 | NCT07691606 | A Study of ARC-02 in B-cell NHL | Taiho Oncology, Inc. | Phase 1 | Recruiting | B-cell Non Hodgkin Lymphoma | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691606) |
| February 20, 2026 | NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | Ascentage Pharma Group Inc. | Phase 1 | Recruiting | Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424833) |
| November 6, 2025 | NCT07225439 | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin... | Sponsor not shown (see the record) | Phase 1 | Recruiting | Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225439) |
| August 14, 2025 | NCT07121946 | This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma | LTZ Therapeutics, Inc. | Phase 1 | Recruiting | Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL)... | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07121946) |
| August 3, 2025 | NCT07101328 | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF\_FRontier-1 ) | Eli Lilly and Company | Phase 1 | Recruiting | Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell... | 215 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07101328) |
| June 17, 2025 | NCT07024147 | JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma | Peking University Cancer Hospital & Institute | Phase 1 | Not yet recruiting | B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma, Follicular Lymphoma, Marginal Zone B Cell Lymphoma, Mantle... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07024147) |
| May 20, 2025 | NCT06980116 | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 | Recruiting | Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)... | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06980116) |
| March 5, 2025 | NCT06859008 | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory... | City of Hope Medical Center | Phase 1 | Recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic... | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859008) |
| November 5, 2024 | NCT06675123 | Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | City of Hope Medical Center | Phase 1 | Recruiting | Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06675123) |
| August 9, 2024 | NCT06544265 | SynKIR-310 for Relapsed/Refractory B-NHL | Verismo Therapeutics | Phase 1 | Recruiting | B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06544265) |
| June 18, 2024 | NCT06464861 | Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 1 | Recruiting | Primary Mediastinal B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma( DLBCL) | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06464861) |
| April 1, 2024 | NCT06340737 | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | Stanford University | Phase 1 | Recruiting | Follicular Lymphoma, Mantle Cell Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma, Marginal... | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06340737) |
| January 17, 2024 | NCT06208735 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | British Columbia Cancer Agency | Phase 1 | Recruiting | B-Cell Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, High-grade... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06208735) |
| January 5, 2024 | NCT06191887 | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for... | Mayo Clinic | Phase 1 | Recruiting | B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06191887) |
| September 7, 2023 | NCT06026319 | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | Sponsor not shown (see the record) | Phase 1 | Recruiting | Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06026319) |
| September 1, 2023 | NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid... | OncoNano Medicine, Inc. | Phase 1 | Recruiting | Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell... | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06022029) |
| August 14, 2023 | NCT05990465 | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | Medical College of Wisconsin | Phase 1 | Recruiting | Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05990465) |
| June 2, 2023 | NCT05887167 | Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy... | Sponsor not shown (see the record) | Phase 1 | Recruiting | Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05887167) |
| March 22, 2023 | NCT05780034 | A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Accutar Biotechnology Inc | Phase 1 | Recruiting | Relapsed/Refractory B-cell Malignancies | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05780034) |
| December 21, 2022 | NCT05659732 | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer | PharmaEngine | Phase 1 | Recruiting | Acute Myeloid Leukemia, Lymphoma, Mantle-Cell | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05659732) |
| November 2, 2022 | NCT05602363 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Carna Biosciences, Inc. | Phase 1 | Recruiting | B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05602363) |
| September 16, 2022 | NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | Schrödinger, Inc. | Phase 1 | Recruiting | Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma... | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05544019) |
| June 27, 2022 | NCT05432635 | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the... | City of Hope Medical Center | Phase 1 | Recruiting | B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05432635) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| City of Hope Medical Center | 3 |
| Nurix Therapeutics, Inc. | 2 |
| Medical College of Wisconsin | 1 |
| University of Colorado, Denver | 1 |
| Mayo Clinic | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| LTZ Therapeutics, Inc. | 1 |
| PeproMene Bio, Inc. | 1 |
| PharmaEngine | 1 |
| [Ascentage Pharma Group Inc.](https://specstream.ai/data/clinical-trials/company/ascentage-pharma-group-inc) | 1 |
| Medolution Ltd. | 1 |
| Verismo Therapeutics | 1 |
| British Columbia Cancer Agency | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| Accutar Biotechnology Inc | 1 |
| [Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd) | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| [Taiho Oncology, Inc.](https://specstream.ai/data/clinical-trials/company/taiho-oncology-inc) | 1 |
| Schrödinger, Inc. | 1 |
| Stanford University | 1 |
| OncoNano Medicine, Inc. | 1 |
| Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 1 |
| Carna Biosciences, Inc. | 1 |
| Newave Pharmaceutical Inc | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 26 |
| Spain | 6 |
| Australia | 5 |
| Italy | 5 |
| Poland | 5 |
| China | 4 |
| France | 4 |
| Canada | 3 |
| United Kingdom | 3 |
| Moldova | 2 |
| Ukraine | 2 |
| Taiwan | 1 |
| Netherlands | 1 |
| Switzerland | 1 |
| Romania | 1 |
| Georgia | 1 |
| Greece | 1 |
| Denmark | 1 |
| Germany | 1 |
| Japan | 1 |
| South Korea | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Medical sciences schools in the United States](https://specstream.ai/data/businesses/medical-sciences-schools/united-states)
- [B2B water treatment companies in the United States](https://specstream.ai/data/businesses/b2b-water-treatment-companies/united-states)
- [Merchandising companies in the United States](https://specstream.ai/data/businesses/merchandising-companies/united-states)
- [Banks in the United States](https://specstream.ai/data/businesses/banks/united-states)
- [Mills in the United States](https://specstream.ai/data/businesses/mills/united-states)
- [Bathtub and sink repair companies in the United States](https://specstream.ai/data/businesses/bathtub-and-sink-repair-companies/united-states)
